Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms

British Journal of Pharmacology

Volumn 169, Issue 5, 2013, Pages 1178-1188

  Arif, I S ^a   Hooper, C L ^a   Greco, F ^a   Williams, A C ^a   Boateng, S Y ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

anti proliferative activity; breast cancer; cardiotoxicity; doxorubicin; melatonin; rosiglitazone

Indexed keywords

CIGLITAZONE; CYCLIN D1; DOXORUBICIN; MELATONIN; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; COLLAGEN; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CELL CYCLE PROGRESSION; CELL DAMAGE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CIRCADIAN RHYTHM; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FIBROBLAST CULTURE; G1 PHASE CELL CYCLE CHECKPOINT; HEART MUSCLE CELL; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; AGONISTS; ANIMAL; BREAST NEOPLASMS; CELL CULTURE; CELL CYCLE; CHRONOTHERAPY; DRUG EFFECTS; FIBROBLAST; MCF 7 CELL LINE; METABOLISM; SARCOMERE;

ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL CYCLE; CELLS, CULTURED; COLLAGEN; DOXORUBICIN; DRUG CHRONOTHERAPY; FEMALE; FIBROBLASTS; HUMANS; LIGANDS; MCF-7 CELLS; MELATONIN; MYOCYTES, CARDIAC; PPAR GAMMA; RATS; SARCOMERES; THIAZOLIDINEDIONES;

EID: 84879012934     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12202     Document Type: Article

References (40)

1. Alao JP, (2007). The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24.
2. Allred CD, Kilgore MW, (2005). Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 235: 21-29.
3. Altun A, Ugur-Altun B, (2007). Melatonin: therapeutic and clinical utilization. Int J Clin Pract 61: 835-845.
4. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM, (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60: 1789-1792.
5. Boateng SY, Hartman TJ, Ahluwalia N, Vidula H, Desai TA, Russell B, (2003). Inhibition of fibroblast proliferation in cardiac myocyte cultures by surface microtopography. Am J Physiol Cell Physiol 285: C171-C182.
6. Camelliti P, Borg TK, Kohl P, (2005). Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 65: 40-51.
7. Demetri G, Le Cesne A, Chawla S, Brodowicz T, Maki RG, Bach B, et al.(2012). First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur J Cancer 48: 547-563.
8. Fan LL, Sun GP, Wei W, Wang ZG, Ge L, Fu WZ, et al. (2010). Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol 16: 1473-1481.
9. Fiegl M, Mlineritsch B, Hubalek M, Bartsch R, Pluschnig U, Steger GG, (2011). Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial. BMC Cancer 11: 373.
10. Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G, (2001). Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer 84: 579-585.
11. Fornari FA, Jarvis W, Grant S, Orr MS, Randolph JK, White FKH, et al. (1996). Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol 51: 931-940.
12. García J, Reiter R, Ortiz G, Oh C, Tang L, Yu B, et al. (1998). Melatonin enhances tamoxifen's ability to prevent the reduction in microsomal membrane fluidity induced by lipid peroxidation. J Membr Biol 162: 59-65.
13. Gewirtz D, (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of thenthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741.
14. Granda TG, Filipski E, D'Attino RM, Vrignaud P, Anjo A, Bissery MC, et al. (2001). Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. Cancer Res 61: 1996-2001.
15. Greco F, Vicent MJ, Gee S, Jones AT, Gee J, Nicholson RI, et al. (2007). Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release 117: 28-39.
16. Hardeland R, (2009). Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors 35: 183-192.
17. How OJ, Larsen TS, Hafstad AD, Khalid A, Myhre ES, Murray AJ, et al. (2007). Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem 113: 211-220.
18. Innominato PF, Levi FA, Bjarnason GA, (2010). Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev 62: 979-1001.
19. Kim KY, Kim SS, Cheon HG, (2006). Differential anti-proliferative actions of peroxisome proliferator-activated receptor-[gamma] agonists in MCF-7 breast cancer cells. Biochem Pharmacol 72: 530-540.
20. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E, et al. (2003). Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92: 715-724.
21. Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, et al. (2008). Disruption of ERa signalling pathway by PPAR y agonists: evidences of PPARc-independent events in two hormonedependentbreast cancer cell lines. Breast Cancer Res Treat 112: 437-451.
22. Liang F, Wang F, Zhang S, Gardner DG, (2003). Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 144: 4187-4194.
23. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, et al. (2004). Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279: 8290-8299.
24. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, et al. (2002). Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 20: 1677-1682.
25. Liu AC, Lewis WG, Kay SA, (2007). Mammalian circadian signaling networks and therapeutic targets. Nat Chem Biol 3: 630-639.
26. Lyles BE, Akinyeke TO, Moss PE, Stewart LV, (2009). Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 8: 268-277.
27. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
28. Ohdo S, Koyanagi S, Matsunaga N, Hamdan A, (2011). Molecular basis of chronopharmaceutics. J Pharm Sci 100: 3560-3576.
29. Oz E, Erbas D, Surucu HS, Duzgun E, (2006). Prevention of doxorubicin-induced cardiotoxicity by melatonin. Mol Cell Biochem 282: 31-37.
30. Palee S, Weerateerangkul P, Surinkeaw S, Chattipakorn S, Chattipakorn N, (2011a). Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart. Exp Physiol 96: 778-789.
31. Palee S, Weerateerangkul P, Surinkeaw S, Chattipakorn S, Chattipakorn N, (2011b). Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart. Exp Physiol 96: 778-789.
32. Ren Y, Sun C, Sun Y, Tan H, Wu Y, Cui B, et al. (2009). PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol 51: 169-174.
33. Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, et al. (2011). Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res 17: 6097-6105.
34. Sahi J, Black C, Hamilton G, Zheng X, Jolley S, Rose K, et al. (2003). Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31: 439-446.
35. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, et al. (2000). Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 83: 1394-1400.
36. Torres TDS, Aguila MB, Mandarim-de-Lacerda CA, (2010). Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring. Pathol Res Pract 206: 642-646.
37. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al. (2000). Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270: 400-405.
38. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS, (2006). Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 13: 401-413.
39. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. (2004). Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109: 3122-3131.
40. Zmrzljak UP, Rozman D, (2012). Circadian regulation of the hepatic endobiotic and xenobitoic detoxification pathways: the time matters. Chem Res Toxicol 25: 811-824.